Pharmaceutical Executive
Drug giant beefs up early-stage R&D, moving into Genentech's turf.
Pharmaceutical Executive-10-11-2006
Pharmaceutical Executive
After axing oncology, Gilead says it's ready for new therapeutic areas.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
